Department of Clinical Chemistry and Laboratory Diagnostics, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.
City Hospitals of Chorzów, 41-500 Chorzów, Poland.
Biomolecules. 2023 Sep 26;13(10):1448. doi: 10.3390/biom13101448.
The aim of our case-control study was to identify novel biomarkers of Crohn's disease (CD) that hold the potential to be employed in both disease diagnosis and monitoring activity. In the context of the contribution of intestinal barrier integrity and immune response to the pathogenesis of CD, we assessed the serum concentrations of proguanylin (pro-GN), pentraxin 3 (PTX3) and S100A12 in 20 patients before and after anti-inflammatory treatment, as well as in 20 healthy individuals. Statistical analyses revealed a significant difference in the levels of pro-GN (5.5 vs. 11.35, < 0.001), PTX3 (2117.9 vs. 1608.37, < 0.05) and S100A12 (79.4 vs. 19.74, < 0.001) between pretreatment patients with CD and healthy individuals. Moreover, we noted a significant relationship between the serum profile of PTX3 and disease activity, expressed as CDAI, both before ( < 0.005, r = 0.63) and after ( < 0.05, r = 0.60) treatment. A similar correlation was noted in the case of S100A12 ( < 0.005, r = 0.81), albeit exclusively within the post-treatment group of patients. Anti-inflammatory treatment resulted in an elevation of pro-GN concentration (5.5 vs. 8.04, < 0.001) and a reduction in PTX3 level (2117.9 vs. 1609.5, < 0.05) in the serum of patients with CD. In comparison to our previous research conducted on a group of patients with ulcerative colitis (UC), those with CD exhibited reduced levels of PTX3 (2117.9 vs. 3197.05, < 0.005) and elevated concentrations of S100A12 (79.4 vs. 39.36, < 0.05). The results obtained from this investigation suggest that measurements of pro-GN, PTX3 and S100A12 could prove beneficial in the diagnosis of Crohn's disease. Assessment of changes in the serum profile of PTX3 appears to be a good marker of response to treatment but also, along with analysis of S100A12 protein serum levels, a useful marker in differentiating CD from UC.
我们的病例对照研究旨在确定克罗恩病（CD）的新型生物标志物，这些标志物有可能用于疾病诊断和活动监测。在肠道屏障完整性和免疫反应对 CD 发病机制的贡献的背景下，我们评估了 20 例接受抗炎治疗前后和 20 例健康个体的血清前胃泌素原（pro-GN）、五聚素 3（PTX3）和 S100A12 浓度。统计分析显示，治疗前 CD 患者与健康个体之间的 pro-GN（5.5 与 11.35， < 0.001）、PTX3（2117.9 与 1608.37， < 0.05）和 S100A12（79.4 与 19.74， < 0.001）水平存在显著差异。此外，我们注意到 PTX3 血清谱与疾病活动之间存在显著关系，用 CDAI 表示，治疗前后均如此（<0.005，r=0.63）。在 S100A12 中也观察到类似的相关性（<0.005，r=0.81），尽管仅在治疗后的患者组中观察到。抗炎治疗导致 CD 患者血清中 pro-GN 浓度升高（5.5 与 8.04， < 0.001），PTX3 水平降低（2117.9 与 1609.5， < 0.05）。与我们之前在溃疡性结肠炎（UC）患者组中进行的研究相比，CD 患者的 PTX3 水平降低（2117.9 与 3197.05， < 0.005），S100A12 浓度升高（79.4 与 39.36， < 0.05）。这项研究的结果表明，测量 pro-GN、PTX3 和 S100A12 可能有助于诊断克罗恩病。评估 PTX3 血清谱的变化似乎是治疗反应的良好标志物，同时分析 S100A12 血清蛋白水平，也是区分 CD 和 UC 的有用标志物。
